Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 12/20 | 0.47 |
| ▸ | EDNRA | P25101 | 12/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18531915 | 1.00 | EDNRB (0.47) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL18531826 | 1.00 | EDNRB (0.47) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL27405573 | 0.84 | EDNRB (0.48) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL14325404 | 0.84 | EDNRB (0.55) | EDNRBEDNRALMNATDP1KDM4E | |
| SCHEMBL14325403 | 0.84 | EDNRB (0.55) | EDNRBEDNRALMNATDP1KDM4E | |
| SCHEMBL9361215 | 0.84 | EDNRB (0.55) | EDNRBEDNRALMNATDP1KDM4E | |
| SCHEMBL12095218 | 0.83 | EDNRB (0.45) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL7808396 | 0.83 | EDNRB (0.45) | EDNRBEDNRACYP1A2LMNATDP1 | |
| SCHEMBL9357252 | 0.81 | SMN1; SMN2 (0.49) | EDNRBEDNRALMNAKDM4EALDH1A1 | |
| SCHEMBL6639188 | 0.80 | CYP1A2 (0.41) | EDNRBEDNRACYP1A2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573907-B2 | 2, 4-pyrimidine derivatives and use thereof | SNU R&DB FOUNDATION (KR) | 2017-02-21 | — | — | US | claimed |
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-20 | — | — | US | claimed |
| EP-2497768-A2 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | SNU R&DB Foundation (KR) | 2012-09-12 | — | — | EP | claimed |
| US-9573907-B2 | 2, 4-pyrimidine derivatives and use thereof | SNU R&DB FOUNDATION (KR) | 2017-02-21 | — | — | US | disclosed |
| EP-2497768-B1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | SNU R&DB FOUNDATION (KR) | 2016-04-20 | — | — | EP | disclosed |
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-20 | — | — | US | disclosed |
| EP-2497768-A2 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | SNU R&DB Foundation (KR) | 2012-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | LY96, AIMP1, NLRP1 | EDNRB 4586/4885EDNRA 4633/4885CYP1A2 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.